Tech Company Financing Transactions

Zyngenia Funding Round

Zyngenia closed a $10 million funding round on 9/7/2012. Backers included private investors.

Transaction Overview

Company Name
Announced On
9/7/2012
Transaction Type
Debt
Amount
$10,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1050 Connecticut Ave. NW 500
Washington, DC 20036
USA
Email Address
Overview
At Zyngenia, we are developing the next generation of antibody-based drugs called Zybody therapeutics. We are spearheading the development of this novel class of drugs to create more potent and more broadly acting protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases.
Profile
Zyngenia LinkedIn Company Profile
Social Media
Zyngenia Company Twitter Account
Company News
Zyngenia News
Facebook
Zyngenia on Facebook
YouTube
Zyngenia on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
David Parkinson
  David Parkinson LinkedIn Profile  David Parkinson Twitter Account  David Parkinson News  David Parkinson on Facebook
Chief Scientific Officer
David Hilbert
  David Hilbert LinkedIn Profile  David Hilbert Twitter Account  David Hilbert News  David Hilbert on Facebook
Vice President
Viktor Roschke
  Viktor Roschke LinkedIn Profile  Viktor Roschke Twitter Account  Viktor Roschke News  Viktor Roschke on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/7/2012: JustFamily venture capital transaction
Next: 9/7/2012: Spreecast venture capital transaction

 

Share this article

 


Where The Data Comes From

Our team works diligently to report on all VC transactions involving tech companies. VC transactions on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary